- Cell Biology
- Product Type
- Research Area
- New Products
- About Tocris
- Contact Us
The MET receptor, also known as hepatocyte growth factor receptor (HGFR), is a proto-oncogenic receptor tyrosine kinase. The endogenous ligand for MET is hepatocyte growth factor/scatter factor (HGF), a disulfide-linked heterodimeric molecule.
|Cat. No.||Product Name / Activity|
|Potent c-MET/ALK inhibitor|
|Potent inhibitor of MET, VEGFR2, Ron and AXL|
|Receptor tyrosine kinase inhibitor, inhibits MET|
|Highly potent HGF/c-MET inhibitor; also AT4 antagonist|
|4239||PF 04217903 mesylate|
|Highly selective MET inhibitor|
|Potent and selective MET inhibitor|
|Selective and potent c-MET kinase inhibitor|
|MET inhibitor. Also inhibits KIT, RET, VEGFR and FLT3|
|Potent c-MET inhibitor; also inhibits other RTKs|
The MET receptor, also known as hepatocyte growth factor receptor (HGFR), is a proto-oncogenic receptor tyrosine kinase. The endogenous ligand for the MET receptor is hepatocyte growth factor/scatter factor (HGF), a disulfide-linked heterodimeric molecule produced predominantly by mesenchymal cells.
In the adult, MET receptor expression is limited to stem and progenitor cells and is necessary for wound healing and hepatocyte regeneration. In the embryo, MET receptors are expressed on cells of epithelial origin. They are essential for invasive growth and mediate epithelial-mesenchymal transition (EMT).
Tocris offers the following scientific literature for MET Receptors to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.